Background: Calcitonin gene-related peptide (CGRP) is a neuropeptide that acts in the trigeminovascular system and is believed to play an important role in migraine. CGRP activates two receptors that are both present in the trigeminovascular system; the CGRP receptor and the amylin 1 (AMY 1 ) receptor. CGRP receptor antagonists, including olcegepant (BIBN4096BS) and telcagepant (MK-0974), can treat migraine. This study aimed to determine the effectiveness of these antagonists at blocking CGRP receptor signalling in trigeminal ganglia (TG) neurons and transfected CGRP and AMY 1 receptors in Cos7 cells, to better understand their mechanism of action. Methods: CGRP stimulation of four intracellular signalling molecules relevant to pain (cAMP, CREB, p38 and ERK) were examined in rat TG neurons and compared to transfected CGRP and AMY 1 receptors in Cos7 cells. Results: In TG neurons, olcegepant displayed signal-specific differences in antagonism of CGRP responses. This effect was also evident in transfected Cos7 cells, where olcegepant blocked CREB phosphorylation more potently than expected at the AMY 1 receptor, suggesting that the affinity of this antagonist can be dependent on the signalling pathway activated. Conclusions: CGRP receptor antagonist activity appears to be assay-dependent. Thus, these molecules may not be as selective for the CGRP receptor as commonly reported.
Introduction
The precise pathophysiology of migraine is unclear, but is hypothesised to involve dysfunction of the trigeminovascular system. This includes the cranial vasculature, the trigeminal ganglia (TG) and the spinal trigeminal nuclei of the brainstem. The TG contains the cell bodies of the sensory trigeminal neurons that transmit signals from the periphery to the brainstem. Calcitonin generelated peptide (CGRP), a 37 amino acid neuropeptide, is believed to play an important role in migraine. For example, during a migraine attack CGRP levels are increased in the blood and infusion of CGRP into migraine sufferers can induce a migraine-like attack (1, 2) . This has resulted in CGRP receiving much clinical attention and in the development of several new investigational drugs against the CGRP system (3,4).
CGRP potently activates two receptors; the CGRP receptor and the AMY 1 receptor, a subtype of amylin receptor that is responsive to both CGRP and the related amylin peptide. The two CGRP receptors are formed by the co-expression of receptor activitymodifying protein 1 (RAMP1) with two different G protein-coupled receptors. The CGRP receptor is formed by RAMP1 and the calcitonin receptor-like receptor (CLR), whereas the AMY 1 receptor is formed by RAMP1 and the calcitonin receptor (CTR) (5) (6) (7) . In the trigeminovascular system, both CGRP and AMY 1 receptors have been identified (8) (9) (10) (11) . However, the majority of research and clinical development has focused upon the CGRP receptor. For example, olcegepant (BIBN4096BS) and telcagepant (MK-0974) are small molecule antagonists that bind to the CGRP receptor and block its activation by CGRP (12) . Olcegepant and telcagepant have both displayed efficacy in clinical trials but have been discontinued (13, 14) . These antagonists are generally considered to be CGRP receptor-specific, however both olcegepant and telcagepant can also act as antagonists at the AMY 1 receptor (8, 15) . The potential biological role of the AMY 1 receptor in CGRP biology and migraine pathogenesis is not yet clear.
Activation of receptors by CGRP results in the induction of a diverse range of downstream signalling pathways that mediate physiological and pathophysiological effects (16) . For example, limited studies in TG and dorsal root ganglia (DRG) neurons have implicated several signalling pathways, including cAMP, cAMP response element-binding protein (CREB), p38 and extracellular signal-regulated kinase (ERK) in CGRP biology (5, (17) (18) (19) (20) . The importance of these pathways in CGRP action or the specific receptor mediating these effects remain unclear.
For pain-relieving drugs, such as morphine, specific signalling molecules are hypothesised to regulate distinct biological effects, including pain relief, tolerance or respiratory dysfunction (21, 22) . This has led to attempts to design drugs that display signalling bias: drugs that preferentially produce signalling associated with pain relief over signalling associated with sideeffects (21, 23) . Given these developments, a deeper understanding of CGRP signalling and the sensitivity of different pathways to CGRP receptor antagonists in neurons is needed. Therefore, in this study we have profiled the ability of CGRP to activate different signalling pathways and examined the sensitivity of these signalling pathways to CGRP receptor blockade in rat TG neurons and compared the outcomes to defined CGRP and AMY 1 receptors in transfected Cos7 cells.
Materials and methods

Isolation and culture of TG neurons
Isolation and culture of TG neurons was performed as described (8, 24) . Briefly, 4-5-day-old postnatal Wistar rat pups were euthanised by decapitation and the TG collected. This model was used because it is an established model for studying trigeminal neuron signalling.
TGs were dissociated by incubation with dispase II (10 mg/mL) for 30 min at 37 C. Cultures were enriched for TG neurons by differential centrifugation through a bovine serum albumin gradient. The TG neuronenriched pellet was re-suspended in TG neuron culture media (L15 medium containing penicillin/streptomycin, glutamine [ 
Phosphorylated ERK histology in TG cultures from Sprague Dawley rats
Glass coverslips were pre-coated with laminin (Gibco, Grand Island, NY, USA) for 1 h at 37 C. Postnatal day 4-5 Sprague Dawley (SD) rats were euthanised by CO 2 asphyxiation and TGs were removed and prepared according to procedures outlined above. Following differential centrifugation, neurons were plated at a concentration of two pups per coverslip in L15 media containing 10% FBS, penicillin/streptomycin, amphotericin B, 50 mM glucose, 250 mM ascorbic acid, 8 mM glutathione and 10 ng/mL NGF (Alomone Labs, Jerusalem, Israel). Cells were serum starved for 10 min, then treated with 100 nM rat aCGRP (Sigma-Aldrich, St. Louis, MO, USA) or 20% FBS (Invitrogen, Eugene, OR, USA) for 7 min. Cells were washed and then fixed with 4% paraformaldehyde for 15 min. Cells were permeabilised using 0.3% Triton X-100. Primary antibodies were raised against phospho-p44/42 MAPK (ERK1/2) raised in mouse (#9101L, Cell Signaling Danvers, MA, USA) and neuron-specific beta III tubulin raised in rabbit (#ab78078, Abcam, Cambridge, MA, USA) and used at 1:200 and 1:300, respectively. Secondary antibodies were anti-mouse or anti-rabbit raised in goat, conjugated to Alexa 488 or Alexa 568 and used at 1:500 (Invitrogen, Eugene, OR, USA). Coverslips were mounted with Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Images were captured using a Zeiss LSM 710 confocal microscope. All images were captured as z stacks under identical exposure conditions. Image J was used for image analysis. Briefly, circular fields surrounding neuron cell bodies were selected and mean grey value in the pERK1/2 channel was measured. The total number of fields measured was 51 neurons from ten random fields for vehicle, 58 neurons from eight random fields for 100 nM raCGRP and 53 neurons measured from 11 random fields for 20% FBS. Animal care and procedures were approved by the University of Iowa Animal Care and Use Committee and performed in accordance with the standards set by the National Institutes of Health.
Cell culture and transfection
Culture of Cos7 cells was performed as previously described (6, 8) . Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 8% heat inactivated FBS and kept in a 37 C humidified 5% CO 2 incubator. Cells were seeded into 96-well plates at a density of 15,000-20,000 cells per well (determined using a Countess Counter TM , Invitrogen) one day prior to transfection. Cells were transiently transfected using polyethylenimine as described previously (6, 8) . Hemagglutinin-tagged human CLR, hemagglutinintagged human CTR (CT (a) subtype) and myctagged human RAMP1 in pcDNA3 or 3.1 plasmid vectors were under the control of the human cytomegalovirus promotor and used as previously described (6, 7) .
Signalling assays in rat TG neurons and transfected cells cAMP assays in TG neurons were performed as previously described (24) . Briefly, assays in TG neurons were performed in serum and NGF-free media containing 0.1% BSA. TG neurons were serum starved for 5 min, then incubated with media alone or 10 pM to 10 mM rat aCGRP with or without antagonists for 30 min at room temperature. cAMP assays were performed with 1 mmol/L 3-isobutyl-1-methylxanthine (IBMX; SigmaAldrich, St.Louis, MO, USA). cAMP content was determined using the LANCE ultra cAMP detection kit (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA). cAMP was measured in transfected Cos7 cells as described previously with minor modifications for use of the LANCE cAMP detection kit (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) (6) . These cAMP assays were also performed with 1 mM IBMX (Sigma-Aldrich, St. Louis, MO, USA). Following incubation with media alone or 1 pM to 1 mM human aCGRP, human amylin or rat amylin in the presence or absence of antagonist for 15 min at 37 C the contents of the wells were aspirated and the reaction stopped by the addition of 50 mL absolute ethanol. cAMP samples were then stored at -30 C for up to seven days before further analysis. Absolute ethanol was evaporated off the cAMP samples in a fume hood and cAMP extracted from dry samples by addition of 40 mL cAMP detection buffer (0.35% Triton X-100, 50 mM HEPES and 10 mM calcium chloride). Samples were then gently shaken at room temperature for 10-15 min. Five microlitres of cAMP sample was then transferred to a white 384 well optiplate and cAMP measured using the LANCE cAMP detection kit (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) as per the manufacturer's instructions. The concentration of cAMP in each sample was determined from a standard curve that was generated in parallel for both LANCE and LANCE ultra assays.
Phosphorylated ERK1/2 (pERK1/2), pCREB and p38 (pp38) were measured using AlphaScreen Surefire or AlphaLisa Surefire ULTRA assay kits (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA). Surefire assays are a well-characterised and sensitive method for the detection of phosphoproteins. These assays display equivalent or greater sensitivity than western blotting and other methodologies (25) (26) (27) . Preliminary time-course experiments were conducted to determine the optimal time to measure signalling (data not shown). Following peptide stimulation at 37 C for 7 min (ERK1/2) or 30 min (CREB and p38), media was removed using an eightchannel aspirator (Cos7 cells) or a 27-gauge syringe (neurons). Twenty microlitres (Cos7) or 6 mL (neurons) of lysis buffer was added to each well and the plates incubated with gentle shaking at room temperature for 10-15 min. Four microlitres of each sample were transferred into a white 384-well optiplate and Surefire assays performed as per the manufacturer's instructions.
All assay plates were read using an Envision plate reader (Perkin-Elmer). Human (h) and rat (r) aCGRP were purchased from American Peptide (Sunnyvale, CA, USA) or Bachem (Bubendorf, Switzerland). rAmylin, raCGRP and haCGRP were purchased from American Peptide (Sunnyvale, CA, USA). hAmylin was synthesised in-house by Fmoc Solidphase peptide synthesis (28) . Peptide content was assumed to be 80% when not known. Olcegepant was kindly provided by Boehringer-Ingelheim (Ingelheim, Germany). Telcagepant was purchased from Suzhou Rovathin Pharmatech Co. (Jiangsu, China). Forskolin (Tocris, Bristol, UK) or FBS were used as positive controls in cAMP and CREB or p38 and ERK1/2 assays, respectively.
Data analysis
All statistical analysis and curve fitting were performed using Graphpad Prism 6.0 (GraphPad Software, San Diego, CA, USA). Maximal signalling responses (E max ) were determined and the data are expressed as a percentage of the E max for the associated control curves to enable combined data to be presented in figures. For pERK1/2 assays in TG neurons the data are expressed as a percentage of 20% FBS. For p38 assays in Cos7 cells, data were normalised to the media only control (basal) and presented as fold basal in concentration-response curve experiments. To define agonist potency, pEC 50 values were obtained by fitting a fourparameter logistic equation to the concentrationresponse curve data. F-tests were then performed to determine if the Hill slope was significantly different from one. For the majority of individual experiments, the Hill slope was not significantly different to unity. Agonist potency curves were therefore re-fitted with a Hill slope constrained to one to obtain pEC 50 values for all experiments. To define antagonist potency, pA 2 values were calculated from pEC 50 values obtained in the presence or absence of antagonist. F-tests were performed within each individual dataset to determine whether the presence of antagonist significantly shifted the concentration response curve. When the majority of individual experiments reported a significant difference, pA 2 values were calculated. For statistical analysis, pEC 50 and pA 2 values from individual experiments were combined and significant differences determined using two-tailed Student's t-tests or one-way ANOVA with post hoc Dunnett's tests. Statistical significance was defined as p < 0.05. All data points represent the mean AE SEM combined from n separate experiments. Separate experiments comprise individual TG neuron or transiently transfected Cos7 preparations, performed with triplicate wells in each experiment.
Results
CGRP stimulation and olcegepant antagonism of cAMP, CREB, p38 and ERK1/2 signalling in TG neurons
In TG neurons, raCGRP increased CREB phosphorylation ( Figure 1a ) and p38 phosphorylation ( Figure 1b ) with potencies that were not significantly different to those observed previously for cAMP (8) (Table 1) . Interestingly, 10 mM raCGRP consistently produced greater CREB phosphorylation than 1 mM, suggesting that CREB activation is biphasic and may involve multiple mechanisms. raCGRP did not induce ERK1/2 phosphorylation in either acute time course (0-30 min using 100 nM raCGRP; data not shown) or concentration response studies ( Figure 1c ). To ensure that the methods used had not failed to detect phosphorylated ERK1/2, the ability of aCGRP to cause ERK1/2 phosphorylation was measured using a distinct histological method. This confirmed a lack of detectable acute ERK1/2 phosphorylation in response to aCGRP in neurons and other cell types present under these conditions (Figure 1d ; quantification not shown). Therefore, ERK1/2 phosphorylation was not measured in further TG neuron experiments.
To better define how olcegepant blocks CGRP activity in TG neurons, the ability of olcegepant to block activation of CREB and p38 was determined. Olcegepant effectively antagonised raCGRP-induced CREB phosphorylation and p38 phosphorylation ( Figure 2 , Table 2 ). p38 phosphorylation was antagonised with similar potency to that observed previously for cAMP accumulation (8) . Surprisingly, antagonism of CREB phosphorylation by olcegepant was approximately 20-fold greater than that observed for cAMP ( Table 2) .
To confirm that CGRP signalling was attributable to TG neurons, we also conducted experiments in TG cultures enriched for non-neuronal glial cells. raCGRP (100 nM) did not stimulate cAMP accumulation or induce ERK1/2, p38 and CREB phosphorylation (Supplemental Figure 1) . However, raCGRP potentiated cAMP accumulation in the presence of 50 mM forskolin, suggesting that these cells have a weak capacity to respond to CGRP.
CGRP stimulation of cAMP, CREB, p38 and ERK signalling at CGRP and AMY 1 
receptors in transfected Cos7 cells
In a transfected Cos7 cell model, haCGRP increased cAMP accumulation (Figure 3a) and CREB phosphorylation ( Figure 3b ) at both CGRP and AMY 1 receptors. The activity of haCGRP at both these receptors was equipotent (Table 1) . Notably, 1 mM haCGRP consistently produced greater CREB phosphorylation than 100 nM at the AMY 1 receptor. This was occasionally observed at the CGRP receptor. Interestingly, no p38 phosphorylation was observed in response to haCGRP in transfected Cos7 cells (Figure 3c , Table 1 ). This suggests that p38 is not coupled to either CGRP or AMY 1 receptor activation in this Cos7 cell model. Despite the lack of raCGRPinduced ERK1/2 phosphorylation in TG neurons, ERK1/2 phosphorylation was measurable in transfected Cos7 cells. In the Cos7 cellular background haCGRP increased ERK1/2 phosphorylation ( Figure  3d ) at both CGRP and AMY 1 receptors with similar potency. ERK1/2 activation was, however, approximately 100-fold weaker than cAMP or CREB activation at CGRP and AMY 1 receptors (Table 1) . These results indicate that cellular background may play an important role in aCGRP-mediated p38 and ERK1/2 activation. Further investigation of p38 or ERK1/2 activation was not conducted in the Cos7 cellular background. Effect of olcegepant on CGRP-stimulated cAMP and CREB signalling at CGRP and AMY 1 receptors in transfected Cos7 cells
Olcegepant antagonised haCGRP-stimulated cAMP accumulation at hCGRP and hAMY 1 receptors (Figure 4a and 4b) . Olcegepant was approximately 130-fold more potent at the hCGRP receptor than the hAMY 1 receptor (Figure 4c , Table 2 ). Olcegepant antagonised aCGRP-stimulated CREB phosphorylation with similar potency to cAMP accumulation at hCGRP receptors ( Figure 4d , Table 2 ). However, mirroring the results observed in TG neurons, at the hAMY 1 receptor aCGRP-stimulated CREB phosphorylation was antagonised significantly more potently than cAMP accumulation (Figure 4e) . Olcegepant was only 26-fold more potent at hCGRP receptors than hAMY 1 receptors ( Figure 4f, Table 2 ). This suggests that blockade of the AMY 1 receptor is responsible for the more potent antagonism of CREB phosphorylation observed for olcegepant in TG neurons. ERK1/2 phosphorylation by aCGRP was too weak to produce meaningful antagonist measurements in transfected Cos7 cells.
Effect of olcegepant on amylin-stimulated cAMP signalling at CGRP and AMY 1 receptors in transfected Cos7 cells
To better define the activity of olcegepant at AMY 1 receptors, the ability of olcegepant to block amylininduced cAMP accumulation was determined ( Figure 5 ). Olcegepant blocked human and rat amylin with pA 2 values of 6.72 AE 0.13 (n ¼ 4) and 6.70 AE 0.20 (n ¼ 3), respectively. Surprisingly, olcegepant was approximately 14-fold more potent at blocking aCGRP than human or rat amylin at AMY 1 receptors (see Table 2 for CGRP data). This suggests that, compared with aCGRP, amylin is relatively resistant to blockade by olcegepant in AMY 1 receptor transfected Cos7 cells and indicates that direct comparisons between aCGRP and amylin signalling behaviours is not straightforward. Experiments with amylin at the CGRP receptor were not performed because amylin is a very weak agonist at this receptor (6, 29) .
Effect of telcagepant and CGRP 8-37 on CGRPstimulated cAMP and CREB signalling at CGRP and AMY 1 
receptors in transfected Cos7 cells
To determine if the more potent antagonism of CREB phosphorylation at the AMY 1 receptor was specific to olcegepant, experiments were repeated with telcagepant. In line with our previous publications, telcagepant antagonised aCGRP-stimulated cAMP accumulation at hCGRP and hAMY 1 receptors (Figure 6a and 6b) .
Telcagepant was approximately 35-fold more potent at hCGRP receptors than hAMY 1 receptors ( Figure 6c , Table 2 ). Antagonism of aCGRP-stimulated CREB phosphorylation by telcagepant was not significantly different to that observed for cAMP accumulation at either hCGRP or hAMY 1 receptors (Figure 6d and 6e), Table  2 ). Telcagepant blocked CREB phosphorylation approximately tenfold more potently at hCGRP receptors than hAMY 1 receptors ( Figure 6f , Table 2 ). This suggests that this mechanism maybe specific to olcegepant; however, as telcagepant is less selective for the hCGRP receptor over the hAMY 1 receptor when measuring cAMP accumulation, this effect may be masked (Table 2) . CGRP is another commonly used antagonist of CGRP responses, although it is not a good discriminator of CGRP and AMY 1 receptors (8). Experiments conducted examining cAMP responses showed that human and rat CGRP displayed no measurable agonist activity at CGRP receptors (Figure 7a) . However, at AMY 1 receptors, both human and rat CGRP displayed weak partial agonist activity (Figure 7b ). At the AMY 1 receptor, human CGRP 8-37 -stimulated cAMP with a pEC 50 of 5.87 AE 0.19 (n ¼ 4) and an E max of 44.17% AE 9.37 (n ¼ 4) compared to aCGRP. Similarly, rat CGRP 8-37 gave a pEC 50 of 7.49 AE 0.22 (n ¼ 4) and an E max of 19.45% AE 2.89 (n ¼ 4). This partial agonism stimulated by CGRP complicates direct comparisons of antagonism at CGRP and AMY 1 receptors and precluded further analysis.
Discussion
Several antagonists of the CGRP receptor, called the 'gepants', have been developed and entered into clinical trials for the treatment of migraine (4). These antagonists have shown great promise. However, currently no gepant has reached the market and several questions regarding efficacy have been raised, leading to the suggestion that other factors may be involved in migraine (30, 31) . We recently showed that the AMY 1 receptor, a second CGRP receptor, was expressed in TG and proposed that this receptor may be important for CGRP activity in migraine (8) . Closer examination of the ability of aCGRP to activate signalling in relevant neurons or at defined CGRP and AMY 1 receptors is required to exploit the CGRP system to its fullest potential. Herein, we report the ability of CGRP to stimulate cAMP production, p38, ERK1/2 and CREB phosphorylation and the signalling molecule-dependent ability of olcegepant to block CGRP action in TG neurons and transfected cells. The binding of CGRP to its receptors is reported to facilitate conformational changes in the receptor that lead to the activation of diverse downstream signalling pathways (16, 32) . The major downstream signalling event described for the activation of both CGRP and AMY 1 receptors is the accumulation of cAMP (6) (7) (8) . We have built on these studies to generate a more complete picture of the pharmacology involved in CGRPmeditated signalling and assess the potential different pathways that could be activated. The activation of the mitogen-activated protein kinase, ERK, has commonly been used as a marker of neuron activation; however, CREB phosphorylation may be appropriate for specific biological functions (18, 33, 34) .
We observed potent aCGRP-stimulated CREB phosphorylation in TG neurons. Similarly, high potency was obtained at CGRP and AMY 1 receptors in Cos7 cells. Although the stimulation of CREB phosphorylation by aCGRP has previously been reported in cultured TG neurons, the potencies of aCGRP and olcegepant have never been quantified for this important signalling molecule (18) . Unexpectedly, olcegepant displayed significantly greater antagonism of aCGRPstimulated CREB phosphorylation compared to cAMP accumulation in TG neurons. Although agonist signalling bias is becoming increasingly common, with reports including both synthetic and natural ligands (22, 24, 35) , signalling molecule-dependent antagonist bias has rarely been reported and is not well described or understood (36) . Given this observation, coupled with the potentially pivotal role CREB plays in biological functions including morphine tolerance and drug dependence/addiction (33, 34, 37, 38) , we examined the ability of olcegepant to block CREB activation at CGRP and AMY 1 receptors. Olcegepant displayed significantly greater antagonism of aCGRP-stimulated CREB phosphorylation than cAMP accumulation at the AMY 1 receptor, but not at the CGRP receptor in transfected Cos7 cells. This suggests that olcegepant may be more active at AMY 1 receptors than is currently appreciated and that the precise signalling mechanisms resulting in CREB activation may differ between CGRP and AMY 1 receptors. Additional experiments examining telcagepant activity in transfected cells suggest that this property maybe unique to olcegepant. However, there was a trend towards reduced selectivity between CGRP receptors for telcagepant when measuring pCREB, suggesting that this effect could extend to other molecules but this would need to be tested in future studies.
The activity of aCGRP and anti-migraine drugs at the AMY 1 receptor should also be considered in regard to potential side-effects, e.g. higher than expected blockade of aCGRP could have potential cardiovascular effects (39) . Given the important role of amylin and amylin receptors in controlling food intake and obesity (40) , chronic blockade of the AMY 1 receptor could have side-effects on metabolism. In the current study, olcegepant displayed relatively low antagonism of amylin compared to aCGRP in AMY 1 receptor transfected Cos7 cells. A similar phenomenon has been observed by others (41) . These findings suggest that at the AMY 1 receptor olcegepant may display agonist-dependent antagonism. However, cells transfected with AMY 1 receptor components are also likely to express amylin-responsive calcitonin receptors which are resistant to olcegepant antagonism (15, 42) . Although, this finding may be an artefact of the cell culture models required to study these receptors, multiple amylin-responsive receptors may be common in a single cell and therefore representative of typical olcegepant 125 (a) (b) hαCGRP hCGRP rCGRP hαCGRP hCGRP rCGRP cAMP ( (44, 45) . Historically, CGRP has been used as a molecular tool to discriminate between the CGRP receptor and other CGRP-responsive receptors, including amylin and adrenomedullin receptors (46, 47) . However, CGRP does not effectively discriminate between CGRP and AMY 1 receptors sufficiently (8) . This is perhaps unsurprising as both CGRP and AMY 1 receptors are effectively activated by CGRP and share a common subunit: RAMP1 (48, 49) . Interestingly, in the current study CGRP displayed partial agonism at transfected AMY 1 receptors. We observed a weak cAMP response to both rat and human CGRP at the AMY 1 receptor, but no response at the CGRP receptor. It is unclear whether the partial agonism we observed at AMY 1 receptors is batch-dependent or cell systemdependent. Interestingly, a similar effect was observed in the first description of CGRP as an antagonist, where LLC-PK 1 cells, which presumably express the calcitonin receptor subunit of an amylin receptor, were weakly activated by CGRP (50) . However, we have not previously observed this level of partial agonism with CGRP , suggesting that there may be variability in CGRP preparations (7, 8) . Variable or batchdependent partial CGRP agonism may result in apparent resistance to this antagonist, particularly as high concentrations are often required to block a response. Therefore, care should be taken when employing this antagonist. For the most effective use of CGRP , its activity should be assessed in well-characterised cell culture models or used at multiple concentrations, to determine if any partial agonism is present. Where practical, the use of a second antagonist, such as olcegepant or AC187 (7, 40) , should also be considered.
Recent focus in the CGRP and migraine field has been on the development of antibodies, designed to block CGRP activity (4, 45) . Anti-CGRP antibodies are currently being designed to block CGRP activity at all potential receptors, including CGRP and AMY 1 , by preventing CGRP from accessing these receptors. This approach is unlikely to feature signalling pathway-dependent antagonism as the receptors should not interact with the antibodies. However, the sites of expression of each receptor (peripheral and/or central) and thus relative accessibility of the antibodies to the receptors would presumably have an impact on efficacy and/or safety. The second approach, exemplified by AMG334, is to develop anti-CGRP receptor antibodies (4, 45) . In principal, a CGRP receptor targeted antibody would not block aCGRP activity at that AMY 1 receptor. This could result in lower efficacy and/or a reduced side-effect profile. The current evidence does not rule out activity for AMG334 at the AMY 1 receptor because the receptor composition of the cells used is undefined (51, 52) . If AMG334 is selective for the CGRP receptor over the AMY 1 receptor, the efficacy of this antibody, coupled with data from the anti-CGRP antibody trials, may shed light onto the role of AMY 1 receptors in migraine. However, the efficacy of a drug/monoclonal antibody depends on the dosage regime, half-life and distribution to the site (or sites) of action, which will likely vary between these treatments. Consequently, clinical data for a single drug, such as AMG334, is unlikely to conclusively show the value of targeting the CGRP receptor over the AMY 1 receptor.
Traditionally, CREB activation is associated with cAMP accumulation; however, in TG neurons CREB phosphorylation was reportedly dependent on Ca2þ/ calmodulin-dependent kinase II, which can act independently of cAMP (18, 53) . Interestingly, the CREB response in TG neurons appeared to be biphasic, indicating the potential presence of a second receptor with significantly lower potency for aCGRP. Given that the biphasic response was also observed at AMY 1 receptors, the calcitonin receptor, which can travel to the cell surface independently of RAMPs, is the likely candidate (7).
The stimulation of ERK phosphorylation by CGRP has been observed in several studies involving both non-neuronal and neuronal tissues (54) (55) (56) (57) . In contrast, we did not observe the acute phosphorylation of ERK1/2 in TG neurons. This difference could be attributed to a lack of direct ERK activation in this cellular background. In other studies, increased ERK phosphorylation could be an indirect effect controlled by secondary factors released by or co-released with CGRP (54, 55) . Interestingly, a recent study reported that infusion of aCGRP into rats did not alter ERK phosphorylation in the TG, supporting the lack of direct activation (58) . We also examined ERK1/2 phosphorylation at CGRP and AMY 1 receptors in Cos7 cells. Consistent with previous studies examining amylin and calcitonin activity at AMY 1 receptors, in Cos7 cells we observed that aCGRP was considerably weaker at activating ERK1/2, compared to cAMP at both CGRP and AMY 1 receptors. This suggests that ERK1/2 activation may occur, at least partly, independently of cAMP accumulation and be activated by G protein-independent mechanisms, such as b-arrestin (16, 59) . Given that the aCGRP-mediated responses we observed were generally less potent in TG neurons than transfected Cos7 cell models, it is possible that the concentrations of aCGRP used in the current study were simply not high enough to elicit an ERK1/2 response in TG neurons. However, a aCGRP-mediated ERK response at concentrations higher than 10 mM is unlikely to be of physiological relevance. We cannot rule out the possibility that high background ERK phosphorylation in our TG neurons could be masking a response in a small proportion of cells. Interestingly, cellular background appeared to be important for p38 phosphorylation. We observed potent raCGRP-mediated p38 phosphorylation in TG neurons; however, in the Cos7 cellular background haCGRP failed to induce a measurable phosphorylation of p38.
An interesting observation in the current study was the apparent lack of CGRP responses from TG glia preparations. CGRP receptor components have been identified histologically in satellite glia (11, 60) . Studies have also shown that $1 mM CGRP can acutely elevate intracellular Ca2þ and chronically induce changes in MAPK signalling and gene transcription in cultured TG glia (61) (62) (63) . On the other hand, we are only aware of a single study that reports cAMP accumulation in response to CGRP in TG glia (64) . Although we observed potent responses to CGRP in TG neurons, 100 nM CGRP did not acutely activate cAMP, ERK1/2, p38 or CREB in our glia-enriched TG cultures. However, 100 nM CGRP amplified forskolin-stimulated cAMP production. This is a well-described phenomenon associated with forskolin co-administration and may indicate low expression of CGRPresponsive receptors in our cellular model (65) . This is consistent with previous reports suggesting that TGderived glia had weaker CGRP receptor staining compared to neurons (66) . It is likely that there is variation between TG glia culture models due to the age and sex of animals used, differential regulation of CGRP receptor components due to differences in culture conditions and time in culture (38) . Inflammatory mediators may also regulate CGRP receptor component or signalling apparatus expression, leading to relative differences in sensitivity to a CGRP stimulus. Further investigation of CGRP responses in TG glia are warranted in future studies.
Despite the importance of CGRP in migraine, the relative involvement of CGRP and AMY 1 receptors in this condition has not been well characterised. It is not known whether activation of either receptor alone is capable of causing a migraine. The presence of the AMY 1 receptor at sites important for migraine pain and the side-effects of pain-relieving medications, coupled with the ability of olcegepant to block CREB activation may have consequences for the design and development of new anti-migraine agents. Our observation of signalling pathway-dependent antagonism by olcegepant illustrates some of the complexity in determining drug affinity, and thus selectivity between receptors. In light of our findings, we propose that the role of AMY 1 in olcegepant activity may be underappreciated and require deeper investigation.
Article highlights
. In trigeminal ganglia neurons and at AMY 1 receptors, olcegepant displayed more potent antagonism of CGRP-stimulated CREB phosphorylation than cAMP accumulation. . CGRP receptor antagonist activity appears to be pathway-dependent and some molecules may not be as selective for the CGRP receptor as is commonly reported.
